• Home
  • About Us
  • Resources
  • Team
    • LEADERSHIP TEAM
    • SCIENTIFIC ADVISORS
    • COMMERCIAL ADVISORS
  • News
    • Press Releases
    • Bridge In The News
    • Other News
  • Contact
Bridge Therapeutics
Bridge Therapeutics

Category: Advisory Board

There are no posts available at present.

Categories
  • Press Releases
  • Bridge In The News
  • Other News

For more information about Bridge Therapeutics please contact us today using the form below.

Investors Click HerePhysicians Click Here

CONTACT US

If you would like to learn more about Bridge Therapeutics please use the contact form below.




    All fields marked with * are required.

    217 Country Club Park
    Ste. 325
    Birmingham, AL, 35213

    T:  +1 205-201-0215

     

    Bridge Therapeutics

    Bridge Therapeutics, Inc. is a development-stage pharmaceutical company pursuing FDA approval of BT‑219, a superior form of buprenorphine-naloxone for opioid use disorder (OUD), and approval of BT-205, a patented drug combination for the treatment of chronic pain in opioid-experienced patients (U.S. Patent #8410092).

    © Copyright Bridge Therapeutics 2025. Bridge Therapeutics is a registered trademark of Bridge Therapeutics Inc.
    All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.